Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AbCellera BiologicsABCL -8.36%53 Degree of Operating Leverage is -0.20 as of Jun. 2026. GuruFocus rates ABCL with a GF Score™ of 53/100 and a GF Value™ of $4.64 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 851 Biotechnology companies, AbCellera Biologics ranks better than 58.4% on this metric.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue.
AbCellera Biologics's Degree of Operating Leverage for the quarter that ended in Jun. 2026 was -0.20. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for AbCellera Biologics's Degree of Operating Leverage or its related term are showing as below:
ABCL's Degree of Operating Leverage is ranked better than 58.4% of 851
companies
in the Biotechnology industry
Industry Median: 0.01
vs ABCL: -0.20
AbCellera Biologics (NAS:ABCL) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
AbCellera Biologics Degree of Operating Leverage Related Terms
AbCellera Biologics Degree of Operating Leverage Historical Data
* Premium members only.
The historical data trend for AbCellera Biologics's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics Degree of Operating Leverage Chart
ABCL vs ANAB, MLTX, SRPT: Degree of Operating Leverage Comparison
For the Biotechnology subindustry, AbCellera Biologics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics Degree of Operating Leverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Degree of Operating Leverage falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
What does a Degree of Operating Leverage of -0.20 mean?
AbCellera Biologics (ABCL) has a Degree of Operating Leverage of -0.20 as of Jun. 2026. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for AbCellera Biologics and its competitors. According to the industry distribution chart, AbCellera Biologics ranks #354 out of 851 companies in the Biotechnology industry, placing it in the top 41.6%.
Is AbCellera Biologics' Degree of Operating Leverage too high?
AbCellera Biologics' current Degree of Operating Leverage is -0.20. Based on the distribution chart, AbCellera Biologics ranks #354 out of 851 companies in the Biotechnology industry, which is above the industry midpoint. Overall, AbCellera Biologics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbCellera Biologics' Degree of Operating Leverage compare to ANAB and MLTX?
According to the Biotechnology industry distribution chart, AbCellera Biologics ranks #354 out of 851 companies for Degree of Operating Leverage. This puts AbCellera Biologics in the upper half of its industry. The industry median Degree of Operating Leverage is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Degree of Operating Leverage for a Biotechnology company?
The median Degree of Operating Leverage among Biotechnology companies is 0.01, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a Degree of Operating Leverage significantly above this median, while those in the bottom quartile fall well below. However, Degree of Operating Leverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Degree of Operating Leverage mean?
A high Degree of Operating Leverage can signal that a stock is expensive relative to its fundamentals. Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. View historical data for AbCellera Biologics and its competitors. For the Biotechnology industry, the median Degree of Operating Leverage is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AbCellera Biologics's current Degree of Operating Leverage is -0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbCellera Biologics stock overvalued right now?
Based on GuruFocus' analysis, AbCellera Biologics (ABCL) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.64, compared to a current price of $11.35 — trading 144.6% above its estimated fair value. The current Degree of Operating Leverage is -0.20. AbCellera Biologics' overall GF Score™ is 53/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Degree of Operating Leverage calculated?
Degree of Operating Leverage is calculated from a company's financial statements. For AbCellera Biologics (ABCL), the current Degree of Operating Leverage is -0.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AbCellera Biologics (ABCL) Overvalued in 2026?
Based on GuruFocus' analysis, AbCellera Biologics stock appears to be overvalued.
The current stock price of $11.35 is trading 144.6% above its estimated GF Value™ of $4.64.
GuruFocus considers AbCellera Biologics to be Significantly Overvalued.
Key valuation signals for ABCL:
Degree of Operating Leverage: -0.20
GF Value™: $4.64 vs. price of $11.35 (144.6% above fair value)
No single metric tells the full story. See the ABCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
53GF Score
Get the complete analysis for ABCL
Degree of Operating Leverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABCL has been successfully added to your 
